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Abstract
Two-stage randomized trials are growing in importance in developing adaptive
treatment strategies, i.e., treatment policies or dynamic treatment regimes. Usu-
ally the ﬁrst stage involves randomization to one of several initial treatments. The
second stage of treatment begins when an early nonresponse criterion or response
criterion is met. In the second stage nonresponding subjects are rerandomized
among second-stage treatments. Sample size calculations for planning these two-
stage randomized trials with failure time outcomes are challenging because the
variances of common test statistics depend in a complex manner on the joint dis-
tribution of time to the early nonresponse criterion or response criterion and the
primary failure time outcome. We produce simple, albeit conservative, sample
size formulae by using upper bounds on the variances. The resulting formulae
only require the same working assumptions needed to size a standard single stage
randomized trial and, in common settings, are only mildly conservative. These
sample size formulae are based on either a weighted Kaplan–Meier estimator of
survival probabilities at a ﬁxed time point or a weighted version of the log rank
test.
KEY WORDS: Dynamic treatment regime; Sample size calculation; Sequential
multiple assignment randomized trial; Weighted Kaplan–Meier estimator; Weighted
log rank test.
1 Introduction
Adaptivetreatmentstrategies, alsocalledtreatmentpoliciesordynamictreatmentregimes
(Robins, 1986; Lavori et al., 2000; Murphy et al., 2001), are growing in importance in
the management of chronic disorders and in the treatment of disorders for which there
are no universally effective treatments. In both cases initial treatments may only be
acutely effective for about 40-60% of the patients; thus multiple stages of treatment are
frequently required to obtain good outcomes. Formally, an adaptive treatment strategy
1is a sequence of decision rules one per stage of the treatment. Each decision rule inputs
patient information and outputs a recommended treatment. Examples of adaptive treat-
ment strategies abound. See McKay et al. (2004), Murphy et al.(2007), and Marlowe
et al. (2008), for an example in the treatment of alcohol dependence, in continuing care
for drug abuse, and in criminology, respectively. The second author is currently collab-
orating with scientists on improving the following simple adaptive treatment strategy
for attention deﬁcit hyperactivity disorder in children: provide behavioral modiﬁca-
tion therapy initially, and beginning at month 2 and every month thereafter, assess the
child’s classroom behavior; if the behavior problems in the classroom exceed a pre-
speciﬁed criterion, then augment the behavioral therapy with methylphenidate.
With the increase in the use of adaptive treatment strategies there has been an in-
crease in calls for clinical trial designs for use in developing these treatment strategies.
Sequential, multiple assignment, randomized trials (Lavori & Dawson, 2003; Murphy,
2005; Murphy et al., 2007) have been proposed. In these trials each subject can pro-
ceed through multiple stages of treatment and may be randomized at each stage among
treatments. Thus each subject may be randomized multiple times through the course of
the trial. Precursors of this design have been used in a variety of medical ﬁelds (Stone
et al., 1995; Tummarello et al., 1997; Rush et al., 2004; Lieberman et al., 2005). In
this paper we focus on a particularly common version of the sequential multiple as-
signment randomized design, a two-stage randomized trial: in the ﬁrst stage subjects
are randomized to one of two initial treatments. The second stage of treatment begins
when and if early signs of nonresponse occur. In the second stage non-responding sub-
jects are rerandomized among two subsequent treatments. Responding subjects stay on
the initial treatment or are assigned another ﬁxed second-stage treatment. Variants of
this design are discussed in the Supplementary Material.
Because sequential multiple assignment randomized trials are intended to provide
data that can be used to assist in the development of an adaptive treatment strategy,
they tend to be sized for comparing two subgroups involved in the trial (Murphy, 2005;
Murphy et al., 2007; Oetting et al., 2007). In the two-stage randomized trial, the two
subgroups might be the two treatments for the nonresponders or alternatively may be
two of the adaptive treatment strategies implemented in the trial (Murphy et al. 2007).
Here we consider sizing the study to compare two adaptive treatment strategies begin-
ning with different initial treatments. In practice these two adaptive treatment strategies
might be the most intensive and the least intensive strategy or might represent opposing
clinical approaches. In general the sequential multiple assignment randomized design
should be followed by a more standard randomized clinical trial, in which the devel-
oped strategy is compared to an appropriate alternative. See the above references for
discussions of these issues.
We focus on sizing a two-stage randomized trial for a failure time outcome, for ex-
ample, time until a ﬁrst school disciplinary event in the case of the following trial for at-
tention deﬁcit hyperactivity disorder or time until treatment dropout in the case of some
schizophrenia and substance abuse trials. This paper is motivated by our experience in
designing several sequential multiple assignment randomized studies, one of which is
the following 36 week trial for attention deﬁcit hyperactivity disorder. The primary
purpose of this trial is to assist clinical scientists in constructing an adaptive treatment
strategy composed of behavioral and/or medication components. In this study children
2with this disorder are ﬁrst randomized to either a low intensity behavioral modiﬁcation
therapy or a low dose of medication. Beginning at 2 months and every month thereafter
each child’s classroom behavior is assessed and compared to a prespeciﬁed criterion.
Exceeding the criterion is interpreted as an early sign of nonresponse; the nonrespond-
ing children are then rerandomized to either intensiﬁcation of current treatment or a
combined treatment. Children who do not show signs of nonresponse continue on their
ﬁrst-stage treatment. The trial design is provided in Figure 1. Although this trial was
originally sized using the outcome of end of school year child behavior problems, one
of the interesting outcomes was the time until a ﬁrst school disciplinary event.
As is clear from the study in attention deﬁcit hyperactivity disorder there are two
time-to-event outcomes, that is, the time to early nonresponse and the time to the pri-
mary outcome. To improve clarity we use the term, failure time, to refer to the time
to the primary outcome. The failure time can occur before or after the time to early
nonresponse, e.g., the time until a ﬁrst school disciplinary event can occur before or
after the child’s classroom behavior meets the criterion for early nonresponse.
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Fig. 1. Design of the trial in attention deﬁcit hyperactivity disorder, abbreviated
ADHD. R: randomization; BT: behavioral therapy; Med: medication; BT+: int-
ensiﬁed behavioral therapy; Med+: higher dose medication; BT&Med: combined
behavioral therapy and medication.
We develop relatively simple, easy to use, sample size formulae for comparing two
adaptive treatment strategies that begin with different initial treatments. We provide
sample size formulae based on two different tests: a test of the equality of survival
probabilities at one time point using a weighted Kaplan–Meier estimator and a test of
the equality of hazard functions based on a weighted version of the log rank test. The
challenge to developing easy to use sample size formulae is that the variances involved
in the test statistics are complex functionals of the joint distribution of time to early
nonresponse and failure time; these two times are likely to be dependent. For exam-
ple, in the study in attention deﬁcit hyperactivity disorder the time to child behavior
exceeding the non-response criterion and the time to a ﬁrst school disciplinary event
are likely dependent.
3To achieve the goal of easy to use sample size formulae, we simplify the formulae
by replacing the variance terms in them by appropriate upper bounds. The resulting
sample size formulae require similar information to that needed to size a two group
randomized trial for a failure time outcome; in particular we need not make assump-
tions concerning the dependence between the time to early nonresponse and the failure
time. To construct the upper bounds we ﬁrst express the variances in terms of potential
outcomes. Second we use time independent weights instead of time dependent weights
to construct the test statistics underlying the sample size formulae. The resulting sam-
ple size formulae will be conservative both due to the use of upper bounds on the
variances and due to the fact that tests which are potentially more efﬁcient than those
used to derive the sample size formulae are used in data analysis. See the next sections
for details about this. However as will be seen, in common settings in which about
40–60% of subjects experience early signs of nonresponse and are thus rerandomized,
these sample sizes are only minimally conservative.
In addition to providing simple, easy to use, sample size formulae, we provide the
asymptotic theory for the weighted Kaplan–Meier estimator. Moreover, we provide
here-to-fore omitted theory justifying the use of the weighted version of log rank test.
Details are provided in the Supplementary Material.
Sample size formulae for sizing two-stage randomized trials for failure time out-
comes have been proposed and studied in Feng & Wahed (2008, 2009). Feng & Wahed
(2009) developed a sample size formula based on a weighted sample proportion es-
timator of survival function whereas Feng & Wahed (2008) developed a sample size
formula based on the supremum of a weighted version of the log rank test. These
formulae require working assumptions on the relationship between the time to early
nonresponse and the failure time. As will be seen these assumptions are unnecessary
in the approach proposed here.
2 Test Statistics
Suppose that n subjects are to be randomized to one of two ﬁrst-stage treatments, de-
noted by A1 = 1; 2. For example, in the study in attention deﬁcit hyperactivity dis-
order these correspond to low intensity behavioral modiﬁcation therapy or low dose
methylphenidate, respectively. Nonresponders are further randomized to one of two
second-stage treatments, denoted by A2 = 1; 2. These could be intensiﬁcation of cur-
rent treatment or augmentation of current treatment, respectively. Recall that respond-
ing subjects are assigned a ﬁxed second-stage treatment which could be the same as the
initial treatment. Let T denote the failure time, S denote the time to early nonresponse
and C denote the censoring time. On each subject we observe A1; R; RA2; S0; 
and U, where R = IfS  min(T;C)g is the nonresponse indicator or equivalently
in this case, the rerandomization indicator, S0 = min(T;S;C),  = I(T  C) and
U = min(T;C). It is worthwhile to mention that, in different trials, the nonresponse,
or alternatively the response, is assessed differently. For example, in some trials it
is assessed at a ﬁxed time point after the initial treatment. Then the deﬁnition of R
should be changed accordingly. However, this will not affect our development in the
sequel, as long as R is the indicator for rerandomization. As is customary, we assume
4throughout that the censoring time C is independent of all other variables including
A1 and A2. Note that S can be censored by either T or C; indeed the failure time T
may occur prior to the time to nonresponse, S. Denote the randomization probabilities
by p = pr(A1 = 1) and q = pr(A2 = 1 j R = 1). Denote jk to be the treatment
strategy for which A1 = j and then A2 = k for nonresponders, for j = 1;2 and
k = 1;2. Finally, the duration of the study is . Data from this trial design provides
information on four adaptive treatment strategies, i.e., strategies 11, 12, 21 and 22.
The trial design described here is just a special case of general two-stage randomized
trial designs. Sample size formulae for other types of trial designs are discussed in the
Supplementary Material.
A variety of statistics have been proposed for comparing two adaptive treatment
strategies with data from two-stage randomized trials and can thus be used to construct
test statistics and related sample size formulae. A ﬁrst approach is to compare survival
probabilities under different strategies at a certain time point, for example, survival
probabilities at the end of the study period. Estimators of survival functions can be
found in Lunceford et al. (2002) who proposed several versions of a weighted sample
proportion estimator, in Wahed & Tsiatis (2006) who derived both a semiparametric
efﬁcient estimator and a less efﬁcient, but easier to implement estimator, in Guo &
Tsiatis (2005) who proposed a weighted Nelson–Aalen estimator of the cumulative
hazard function, and recently, in Miyahara & Wahed (2010) who proposed a weighted
Kaplan–Meier estimator. A second approach is to compare survival functions of the
two adaptive treatment strategies using a weighted version of the log rank test as in a
2005 PhD thesis by Xiang Guo at the Department of Statistics, North Carolina State
University, which can be found at: http://www.lib.ncsu.edu/resolver/1840.16/5768.
We utilize test statistics based on the two approaches discussed above to derive
samplesizeformulae. Inthefollowingweconsiderpoweringthetwo-stagerandomized
trial to detect a difference, if any, between strategies 11 and 21. Comparisons between
strategies 12 and 21, 11 and 22, and 12 and 22 are similar. In the context of the study in
attention deﬁcit hyperactivity disorder this means that the trial is sized to ensure power
to compare two competing approaches to clinical management of the disease: using
behavioral modiﬁcation therapy with intensiﬁcation if needed, which is favored by
clinical psychologists, versus using medication with intensiﬁcation if needed, which is
favored by physicians. Since only strategies 11 and 21 are considered in the following,
to simplify notation, from here on we denote the survival function, cumulative hazard
function and hazard function of the failure time under strategy 11 as  F1(t), 1(t) and
1(t) and those under strategy 21 as  F2(t), 2(t) and 2(t).
All of the statistics discussed above involve weights, which come in two forms:
time independent weights or time dependent weights. Weights are required because in
this design, for any given adaptive treatment strategy, responding subjects who have
an initial treatment consistent with this strategy are over represented in this strategy
and nonresponding subjects who have an initial treatment consistent with this strategy
are under represented. For example, all subjects starting with A1 = 1 who responded
have a treatment sequence that is automatically consistent with strategy 11, while only
a proportion of subjects started with A1 = 1 who failed to respond have a treatment
sequence that is consistent with strategy 11, which depends on the second randomiza-
tion probability q. To adjust for this design characteristic we use inverse probability
5weights (Robins et al., 1994; Murphy et al., 2001):
Wj =
I(A1 = j)
p

1   R +
I(A2 = 1)
q
R

; j = 1;2;
for strategies 11 and 21, respectively, where I() denotes the indicator function. These
weights are similar to the weights used in Lunceford et al. (2002) and Miyahara &
Wahed (2010). The difference is that they consider strategies with the same ﬁrst-stage
treatment and hence the factors I(A1 = 1)=p and I(A1 = 2)=(1   p) are omitted.
Alternatively one could use time dependent weights:
Wj(t) =
I(A1 = j)
p

1   R(t) +
I(A2 = 1)
q
R(t)

; j = 1;2;
where R(t) = IfS  min(t;T;C)g. These time dependent weights are used in
Guo’s dissertation and by Feng & Wahed (2008). Time dependent weights permit
more subject information to be used in the estimation at each time t. Consider strategy
11 and subjects who have A1 = 1 as the initial treatment. If time dependent weights
are used then all of these subjects have a nonzero time dependent weight at time points
t less than min(S;T;C), i.e., before they meet the nonresponse criterion, regardless
of the value of A2. However, if time independent weights are used then those subjects
who have A2 = 2 will never have a nonzero weight for strategy 11. Hence, intuitively
the use of time dependent weights results in efﬁciency gains compared with the time
independent weights.
We ﬁrst consider the test statistic based on the weighted Kaplan–Meier estimator.
This test statistic is used for testing for H0 :  F1(t) =  F2(t) versus H1 :  F1(t) 6=  F2(t)
for some t satisfying 0 < t  . It is based on the weighted Kaplan–Meier estimator
of  Fj(t) as proposed by Miyahara & Wahed (2010), which is deﬁned as
^  FKj(t) =
Y
ut

1  
Pn
i=1 Wji(u)dNi(u)
Pn
i=1 Wji(u)Yi(u)

; j = 1;2; (1)
where the subscript i indicates the ith subject, i = 1;:::;n and N(u) = I(U  u)
is the counting process for the failure time, and Y (u) = I(U  u) is the at risk pro-
cess. The estimator in (1) uses time dependent weights; however we can also use time
independent weights by replacing Wji(u) with Wji in (1). As will be discussed in Sec-
tion 3, we will use the test statistic based on weighted Kaplan–Meier estimator with
time independent weights for sample size calculation, while in data analysis for eval-
uating the sample size formula the test statistic with time dependent weights will also
be considered. It is worth mentioning that another estimator of  Fj(t) can be deﬁned as
expf ^ j(t)g, where ^ j(t) is the weighted Nelson–Aalen estimator of j(t) proposed
in Guo & Tsiatis (2005). Theorem 1 in the Supplementary Material implies that the
asymptotic distribution of the weighted Kaplan–Meier estimator is the same as that of
this estimator.
ByTheorem1intheSupplementaryMaterial, theasymptoticdistributionofn1=2f^  FKj(t) 
 Fj(t)g is Nf0;2
Kj(t)g, where
2
Kj(t) =  F2
j (t)E
Z t
0
Wj(u)
 Fj(u)  FC(u)
fdN(u)   Y (u)dj(u)g
2
:
6Let ^  FC(u) be the usual Kaplan–Meier estimator of  FC(u). From this result, a test
statistic for testing H0 :  F1(t) =  F2(t) for some 0 < t   can be constructed as
TK(t) =
n1=2f^  FK1(t)   ^  FK2(t)g
f^ 2
K1(t) + ^ 2
K2(t)g
1=2 ;
where
^ 2
Kj(t) =
^  F
2
Kj(t)
n
n X
i=1
"Z t
0
Wji(u)
^  FKj(u)^  FC(u)
fdNi(u)   Yi(u)d^ Nj(u)g
#2
is a consistent estimator of 2
Kj(t), for j = 1;2. The variance of the numerator of
the test statistic is the sum of variances since ^  FK1(t) and ^  FK2(t) are independent.
This independence occurs because the two strategies begin with different treatments;
when the strategies begin with the same treatment, the Kaplan–Meier estimators are
dependent. See the Supplementary Material, in the paragraph following the proof of
Theorem 1, for details regarding this situation. If time independent weights are used in
the weighted Kaplan–Meier estimator then Wj(u) and Wji(u) in the above expressions
for 2
Kj(t) and ^ 2
Kj(t) are replaced by Wj and Wji, respectively, and the resulting
estimators of variances remain consistent. Under the null hypothesis, the test statistic
TK(t) has an asymptotic N(0;1) distribution.
Now we consider the weighted log rank statistic. This test statistic is used for
testing H0 :  F1   F2 versus H1 :  F1(t) 6=  F2(t) for some t  . The log rank test
is the most commonly used test for comparing the distributions of two failure times. It
is also commonly used to calculate sample sizes in classical survival analysis. See, for
example, Schoenfeld (1981). Weighting each subject as above, the following statistic
is an analogue of the usual log rank statistic:
Ln =
Z 
0
 YW2(t)
 YW1(t) +  YW2(t)
d  NW1(t)  
Z 
0
 YW1(t)
 YW1(t) +  YW2(t)
d  NW2(t);
where  YWj(t) =
Pn
i=1 Wji(t)Yi(t)=n and d  NWj(t) =
Pn
i=1 Wji(t)dNi(t)=n. This
test statistic, which was proposed in Guo’s dissertation, uses time dependent weights.
Onecanusetimeindependentweightsaswell, justbyreplacingWji(t)inthedeﬁnition
with Wji. By Theorem 3 in the Supplementary Material, the asymptotic distribution of p
nLn under the null hypothesis is Nf0;(2
L1 + 2
L2)=4g, where
2
Lj = E
Z 
0
Wj(t)fdN(t)   Y (t)d1(t)g
2
; j = 1; 2:
Again, see the Supplementary Material, the paragraph following the proof of Theorem
3, for testing two strategies starting with the same initial treatment. Let
^ 2
Lj =
1
n
n X
i=1
Z 
0
Wji(t)fdNi(t)   Yi(t)d^ 1(t)g
2
; j = 1;2;
7where
d^ 1(t) =
Pn
i=1 W1idNi(t) +
Pn
i=1 W2idNi(t)
Pn
i=1 W1iYi(t) +
Pn
i=1 W2iYi(t)
is obtained by pooling the two groups. We can use the following test statistic to test for
H0 :  F1   F2:
TL =
2n1=2Ln
(^ 2
L1 + ^ 2
L2)
1=2:
This test statistic also has an asymptotic N(0;1) distribution under H0. Again, when
time independent weights are used, we simply replace Wj(u) and Wji(u) in the above
expressions by Wj and Wji, respectively. We will use the test with time independent
weights for sample size calculation but for data analysis we also consider the test with
time dependent weights. The weighted log rank test here is different from the test with
the same name in classical survival analysis. We used this name because it is consistent
with the terminology used for the weighted Kaplan–Meier estimator and with the liter-
ature in this area. Lastly, Lokhnygina & Helterbrand (2007) proposed a pseudo score
test of the log hazard ratio in a Cox proportional hazards model for comparing two
adaptive treatment strategies. In their pseudo score function, each subject is weighted
by a time independent weight. The statistic Ln deﬁned above with time independent
weights is equivalent to the pseudo score function deﬁned there, but their expression of
its asymptotic variance is in a different form.
3 Sample Size Calculation
As mentioned above, we propose to use time independent weights in the test statistics
forsamplesizecalculation. Thisisbecausethetimeindependentweightsmakeiteasier
to obtain simple upper bounds on variances involved in the test statistics. These upper
bounds are crucial in obtaining comparatively simple sample size formulae, which will
be seen below. On the other hand we suggest that test statistics using time dependent
weights be used in the data analyses as these tests are potentially more powerful. We
ﬁrst derive sample size formulae using exact variances, and then replace the variances
in the sample size formulae with their upper bounds to get our ﬁnal sample size formu-
lae.
First suppose that we wish to test H0 :  F1(t) =  F2(t) versus H1 :  F1(t) 6=  F2(t)
for some t satisfying 0 < t   using the test based on the weighted Kaplan–Meier
estimator with time independent weights. For deﬁniteness, we suppose that the survival
probabilities at the end of the study are to be compared, i.e, t = , and write TK
instead of TK(). Under signiﬁcance level , the rejection region of a two-sided test
of H0 :  F1() =  F2() is fjTKj > Z1  
2 g. By Theorem 1 in the Supplementary
Material, the distribution of TK is approximately normal with mean n1=2f  F1()  
 F2()g=

2
K1() + 2
K2()
	1=2
and variance 1 under the alternative hypothesis. To
detect a difference in survival probabilities at time  of size K =  F1()   F2() with
power 1   , we set
pr
 
TK > Z1  
2 or TK <  Z1  
2

= 1   ;
8which yields the sample size formula
nK 
(Z1  
2 + Z1 )2 
2
K1() + 2
K2()
	
  F1()    F2()
	2 :
Next suppose that we wish to test H0 :  F1   F2 versus H0 :  F1(t) 6=  F2(t) for
some t   and the weighted log rank test with time independent weights is used. To
construct a sample size formula based on the log rank test or its variants, the asymp-
totic distributions of the test statistics are usually derived under a proportional hazards
assumption with a local alternative for the log hazards ratio (Schoenfeld, 1981; Chow
et al., 2005; Eng & Kosorok, 2005; Feng & Wahed, 2008). The proportional hazards
assumption is 2(t) = 1(t)e, where  is the log hazard ratio. And the local alter-
native assumption we use is represented by  = =n1=2 for some constant . The
use of a local alternative greatly simpliﬁes the asymptotic means of the test statistics,
which facilitates the sample size calculation. We use this approach here as well. Guo’s
dissertation studied the asymptotic distribution of the weighted log rank statistic Ln
with time dependent weights. While he provided an outline, we provide a complete
proof of the asymptotic normality of Ln under the local proportional hazards alterna-
tive in the Supplementary Material. Based on the asymptotic distribution of Ln given
in Theorem 3 in the Supplementary Material and using a similar derivation as above,
the corresponding sample size formula can be obtained as
nL 
 
Z1  
2 + Z1 
2  
2
L1 + 2
L2

2 R 
0
 FC(t)dF1(t)
	2 :
To use the above formulae to calculate sample sizes we need values of 2
K1() and
2
K2() or 2
L1 and 2
L2. A challenge is that, even with time independent weights, these
variances depend in a complex manner on the joint distribution of the failure, T, and
time to early nonresponse, S. In particular, R in the weight functions W1 and W2 de-
pends on S; furthermore, as discussed in the Supplementary Material, the weights are
not predictable, thus one cannot simplify the variance formulae by the usual martin-
gale arguments. Thus a direct approximation of the values for these variances requires
working assumptions on the joint distribution of T and S. We avoid making work-
ing assumptions on the joint distribution by the use of upper bounds on the variances;
this then permits the use of working assumptions similar to those used to size standard
one-stage trials.
To obtain interpretable upper bounds on the variances, we use potential outcomes
(Holland, 1986) notation. The use of potential outcomes permits us to form upper
bounds that are easily interpretable to scientists and thus enables the scientist to more
easily provide the necessary information needed in the sample size calculation. Fur-
thermore the potential outcome notation allows us to make our arguments precise. Let
Sj and ~ Tj be the time to early nonresponse and the failure time, respectively, if a
subject is assigned ﬁrst-stage treatment j. The ~ Tjs correspond to failure times in a
one-stage study; that is, a study in which there is no change in treatment assignment. If
Sj < ~ Tj then deﬁne Djk to be the interval of time between early nonresponse and the
failure time if the subject is assigned second-stage treatment k. Intuitively the failure
9time in response to the adaptive treatment strategy, jk, is the mixture of two times, one
failure time in which there would have been no further treatment assignment, and the
other failure time in which there would be a further treatment assignment once early
nonresponse occurs. That is, the potential failure time under the assignment of strategy
jk is Tjk = ~ TjI(Sj > ~ Tj) + (Sj + Djk)I(Sj  ~ Tj). On the event fSj > ~ Tjg,
Tj1 = Tj2. We make the following consistency assumptions (Robins, 1997). If a sub-
ject is assigned ﬁrst-stage treatment j then the time to early nonresponse S is equal to
Sj; similarly if the assigned ﬁrst-stage treatment is j, then T = Tjk for all nonrespond-
ing subjects assigned second-stage treatment k. The failure time for all responding
subjects satisﬁes T = Tjk for k = 1;2.
Now consider the variance term 2
K1(). First, when W1 6= 0, N(t) = I(T  t)
and Y (t) = I(U  t) can be replaced by N1(t) = I(T11  t;T11  C) and Y1(t) =
Ifmin(T11;C)  tg, respectively. Thus
2
K1() =  F2
1()E
Z 
0
W1
 F1(t)  FC(t)
fdN1(t)   Y1(t)d1(t)g
2
:
Next since N1(t) and Y1(t) are functions of T11 and C only, and the weight is time
independent, the above is
2
K1() =  F2
1()E
 
E(W2
1 j T11;C)
Z 
0
1
 F1(t)  FC(t)
fdN1(t)   Y1(t)d1(t)g
2!
:
Because the randomization of ﬁrst-stage and second-stage treatments ensures that A1
and A2 are independent of the potential outcomes for the Sjs and the Tjks, we can
replace E(W2
1jT11;C) in the above display by E(1   R + R=q j T11;C)=p. Next
replace R by 1 to produce the upper bound,
2
K1() 
 F2
1()
pq
E
Z 
0
1
 F1(t)  FC(t)
fdN1(t)   Y1(t)d1(t)g
2
=
 F2
1()
pq
Z 
0
d1(t)
 F1(t)  FC(t)
; (2)
where martingale theory is used to obtain the integral in the last equality. An upper
bound for 2
K2() is obtained similarly, and it is the bound where we replace p with
(1   p) and the subscript 1 by subscript 2 in (2). A similar argument can be used to
derive the upper bounds for 2
L1 and 2
L2 as well; in the case of 2
L1 the upper bound is
2
L1 
1
pq
Z 
0
 FC(t)dF1(t):
The upper bound on 2
L2 is similar, but p is replaced by (1   p) and the subscript 1 is
replaced by subscript 2.
Since the upper bounds are obtained by replacing R with 1, the larger proportion of
subjects randomized at the second stage, or equivalently, the larger proportion of non-
responders, the sharper the upper bounds. In the case that every subject is randomized
10at the second stage, for example, if all subjects are nonresponders, the upper bounds
are precise.
Now replacing the variances in the above sample size formulae by their upper
bounds, the sample size based on the weighted Kaplan-Meier estimator with time in-
dependent weights and upper bounds on the variances is
nK 
 
Z1  
2 + Z1 
2
2
B
  F1()    F2()
	2 ; (3)
where
2
B =
 F2
1()
pq
Z 
0
d1(t)
 F1(t)  FC(t)
+
 F2
2()
(1   p)q
Z 
0
d2(t)
 F2(t)  FC(t)
:
In a similar manner, the sample size based on the weighted log rank test with time
independent weights and upper bounds on the variances is
nL 

1
pq
+
1
(1   p)q
  
Z1  
2 + Z1 
2
2 R 
0
 FC(t)dF1(t)
: (4)
In order to calculate the sample size using formula (4), we only need information
about the hazard ratio and the integral
R 
0
 FC(t)dF1(t), which is exactly equal to the
probability of observing an event before time  when all subjects are assigned strategy
11. This is the same information used to size a two-arm one-stage trial using the log
rank test (Schoenfeld, 1981). In contrast, if we use formula (3) to calculate the sample
size, we need working assumptions on the distribution function of the potential fail-
ure time under each strategy, i.e., F1(t) and F2(t), as well as FC(t), the distribution
function of the censoring time. In practice, one could assume these functions have a
parametric form, for example, exponential or Weibull distributions. For the censoring
distribution  FC(t), a uniform distribution over (0;) with a point mass at  is often
reasonable. Then one only needs to guess at the parameters in these distributions to
calculate the integrals in the formula. Alternatively, one could make guesses at these
distribution functions at some ﬁxed time points before , and then approximate the
integrals using numerical approximation.
Although formula (3) needs more inputs than (4), it is made much simpler by using
upper bounds on variances. We illustrate this by comparing our working assumptions
needed for (3) with those in a sample size formula developed by Feng & Wahed (2009).
Their sample size formula is also based on testing the equality of survival probabilities
at a ﬁxed time point but using the second weighted sample proportion estimator with
time independent weights proposed in Lunceford et al. (2002). Instead of forming
upper bounds on the variances, they simplify the variance terms by making working
assumptions on the joint distribution of the potential outcomes. They use slightly dif-
ferent potential outcomes than used here. In their setting Rj denotes the nonresponse
indicator under ﬁrst-stage treatment j; Tj0 is the failure time if the subject responds and
T
jk is the failure time if the subject does not respond and is assigned treatment k in the
second stage. Both times are durations beginning at the start of ﬁrst-stage treatment.
Then the failure time in response to strategy jk is Tjk = (1 Rj)Tj0 +RjT
jk. Using
11these potential outcomes they assume that E(Rj j Tjk) = E(Rj). See, for example,
their derivation of display (12) and their simulation models. One might interpret this
working assumption as: the chance that a subject exhibits early nonresponse is inde-
pendent of the subject’s failure time. Since they do not use upper bounds on variances,
they need to make more working assumptions than our formula (3). Besides the as-
sumption just mentioned, they also need assumptions about the distribution functions
of Tj0 and T
jk, and the nonresponse rates pr(Rj = 1), j;k = 1;2, to calculate the
sample size.
We further compare working assumptions used by the different sample size formu-
lae in the context of the trial for attention deﬁcit hyperactivity disorder. First consider
sizing the trial to test if the chance of a school disciplinary event occurring by 36 weeks
differs between strategies 11 and 21. In this example, the working assumption required
to use the formula in Feng and Wahed (2009) is that, for both initial treatments, early
nonresponse is independent of the time to a school disciplinary event. Moreover, to
apply their formula, we need to know the distribution functions of the times to a school
disciplinary event for both those who respond to behavioral therapy and those who
respond to medication. We also need to know the distribution functions of time to a
school disciplinary event for those who do not respond to behavioral therapy and are
then assigned more intensiﬁed behavioral therapy, and for those who do not respond to
medication and are then assigned higher dose medicine, respectively. Lastly, we need
to know the proportion of subjects who respond to behavioral therapy and proportion of
subjects who respond to medication. In contrast, the sample size formula (3) does not
require the independence assumption stated above. Moreover, we only need to know
the distribution functions of time to a school disciplinary event for subjects who are
assigned strategy 11 and 21, respectively. If instead we wish to size the trial to test the
difference between the distributions of the times to a school disciplinary event under
strategies 11 and 21 using the weighted log rank test, then the working assumptions are
even simpler. To use the sample size formula (4), our ﬁrst assumption is proportional
hazards between strategies 11 and 21. In addition, we need to specify the hazard ratio
and the probability of observing the ﬁrst school disciplinary event before the end of
study in children who are assigned strategy 11. The working assumptions in general
settings for the three sample size formulae are provided in Table 1.
“Table 1 about here.”
4 Simulation
We conducted a simulation study to assess the performance of the sample size formu-
lae. In evaluating the formulae we include tests based on time independent weights and
tests based on time dependent weights. Moreover, for comparing the survival proba-
bilities at a given time point, we include two additional tests. The ﬁrst test is based
on a slight generalization of the third weighted sample proportion estimator of  Fj(t)
in Lunceford et al. (2002), which is the most efﬁcient among the three estimators pro-
posed there. Our generalization uses time dependent weights W1(t) and W2(t) instead
of the time independent weights. The second test is based on the pseudo semiparamet-
12ric efﬁcient estimator of  Fj(t) proposed by Wahed & Tsiatis (2006).
In the simulations, we suppose  = 36. We generate (Tj1;Sj) jointly from a Frank
copula model (Roger, 1998) with association parameter 5 when j = 1 and 6 when
j = 2, resulting in a positive correlation between the failure time and the time to early
nonresponse. The marginal distributions of T11 and T21 are Weibull distributions, with
a common location parameter equal to 2 to ensure proportional hazards. The scale
parameter for T11 is 50 and the scale parameter for T21 is determined by the desired
hazard ratio. The hazard ratio takes values 1.25, 1.5 or 2.0. The marginal distribu-
tions of the times to early nonresponse, S1 and S2, also have Weibull distributions
with both scale and location parameters varied so as to achieve varying percentages of
subjects who are randomized in the second stage. Speciﬁcally, the percentage of sub-
jects randomized at the second stage ranges from about 25% to about 75% throughout.
The censoring time, C, has a point mass at  and is otherwise uniformly distributed
over (0;), and is independent of all other variables. The size of the point mass at
 is varied so that approximately 20% or 40% of the failure times are censored. The
survival probabilities at the end of study under the two strategies 11 and 21 range in
(0:4;0:6) among all scenarios. The ﬁrst- and second-stage randomization probabili-
ties are p = q = 0:5. All simulations are based on 1000 simulated data sets. The
signiﬁcance level is  = 0:05 and the desired power is 80%.
Table 2 and Table 3 provide the results of the simulation. From both tables, we
observe that the desired power is achieved by all the tests except the one based on the
third estimator in Lunceford et al. (2002) when comparing survival probabilities at the
end of study. The tests based on time dependent weights are more efﬁcient than the cor-
responding tests based on time independent weights. By results in Table 2, the pseudo
efﬁcient estimator of Wahed and Tsiatis is slightly more efﬁcient than the weighted
Kaplan–Meier estimator with time dependent weights when the sample sizes are large.
In smaller samples, the efﬁciency of the pseudo efﬁcient estimator is reduced due to
the variability introduced by the estimation of probabilities of potentially rare events.
See Wahed & Tsiatis (2006) for details. Table 2 also includes sample sizes calculated
from the formula in Feng & Wahed (2009). This sample size formula assumes that
the potential outcomes Rj and Tjk are independent; this assumption does not hold
here. Their sample sizes are a little larger than those calculated from our formula (3).
This is possibly due to the relatively low efﬁciency of the sample proportion estimator
compared with the weighted Kaplan-Meier estimator.
“Table 2 about here.”
“Table 3 about here.”
From Tables 2 and 3 we also observe that the degree of conservatism of the sample
size formulae depends on the percentage of subjects randomized at the second stage.
The higher percentage of subjects randomized at the second stage, the less conservative
the sample sizes. Notably, when the percentage of subjects who are randomized at the
second stage approaches or exceeds 70%, the achieved powers are close to the expected
power. We can also use simulations to search for the nonconservative sample sizes and
compare them with our conservative ones. For example, when the hazard ratio is 1.5,
and when 25%, 50% and 75% subjects are rerandomized, the sample sizes needed to
13guarantee 80% power using the test based on weighted Kaplan–Meier estimator with
time independent weights are about 680, 710 and 770, respectively, compared with
880 subjects required by our conservative sample size formula. When the weighted
log rank test with time independent weights are used, the nonconservative sample sizes
are about 620, 690 and 720, when 25%, 50% and 75% subjects are rerandomized,
respectively, while our conservative sample size is 753.
Table 4 presents the results of another simulation which illustrate the achieved pow-
ers when working assumptions are incorrect, that is, the quantities needed to calculate
the sample sizes are misspeciﬁed. We consider cases where the hazard ratio is 1.25 or
1.5. In the case of the sample size formula (3), the wrong scale or shape parameter
is used in the speciﬁcation of the Weibull distributions of T11 and T21. In the case
of the sample size formula (4), the probability of observing an event before the end
of study is misspeciﬁed. The results show that, the desired powers for both tests are
usually achieved or approximated under reasonable degree of misspeciﬁcation. This
robustness is a consequence of conservatism of the sample size formulae.
“Table 4 about here.”
In all these simulations we generated data in which the failure times and the times
to early nonresponse are positively associated. We also conducted simulations in which
they are negatively associated; the results are very similar to those shown here.
5 Discussion
Although the focus of this work is on trials intended for use in reﬁning or developing
adaptive treatment strategies, in some situations two fully developed adaptive treatment
strategies exist and scientiﬁc interest rest primarily in contrasting the strategies. In this
case a traditional two-arm trial of the strategies is more appropriate than the sequential
multiple assignment randomized trial discussed here and has the advantage of requiring
a smaller sample size.
In this work we assume that the censoring time distribution does not depend on the
initial treatment. In the case of the weighted log rank test, removing this assumption
will result in a more complicated sample size formula. However, removing this as-
sumption for the sample size formula based on the weighted Kaplan–Meier estimator
requires minimal change as follows. Denote  FCj(t) to be the survival function of the
censoring time for subjects starting with initial treatment A1 = j, j = 1;2. Then it
is easy to see that the asymptotic distribution of ^  Fj(t) is normal with the same mean
but  FC(t) in the variance formula is replaced by  FCj(t). Therefore, the corresponding
sample size formula is the same as formula (3) except that 2
B now becomes
2
B =
 F2
1()
pq
Z 
0
d1(t)
 F1(t)  FC1(t)
+
 F2
2()
(1   p)q
Z 
0
d2(t)
 F2(t)  FC2(t)
:
The simulation results in the previous section indicate that the sample sizes ob-
tained using the weighted log rank test are usually considerably smaller than those
obtained from comparing survival probabilities at a given time point. Moreover, less
14information is needed to calculate the sample size derived from the weighted log rank
test. Hence we have developed a Web applet which can be used to size studies based
on the weighted log rank test. This Web applet, along with the simulation code for our
simulations, can be found at http://methodologymedia.psu.edu/logranktest/samplesize.
However, the log rank test is designed to have highest power against proportional haz-
ards (Peto & Peto, 1972), thus the use of the sample size formula based on the log rank
test may not provide the desired power if the hazards under the alternate hypothesis are
likely nonproportional. The test for equality between survival probabilities at one time
point has a more modest goal, hence may be better able to ensure power.
Feng & Wahed (2008) derived a sample size formula for the same problem using a
supremum weighted log rank test comparing two strategies. Their sample size formula
requires more detailed working assumptions than that required by the formula based
on the weighted log rank test given here. It would be desirable to develop a sample
size formula based on the supremum weighted log rank test that requires less detailed
working assumptions.
SUPPLEMENTARY MATERIAL
Supplementary Material available at Biometrika online includes a discussion of sample
size formulae for two variants of two-stage randomized trials and proofs of theoretical
results.
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17Table 1: Methods for sample size calculation, working assumptions made, and quanti-
ties needing to be guessed to calculate the sample size
Method Working assumptions Quantities needing to be guessed
cWKM none  Fj(t); j = 1;2; and  FC(t)
the response status is independent pr(Rj = 1),  Fj0(t),  F
j1(t);
cWSP of the potential failure time j = 1; 2, and  FC(t)
hazard ratio,
cWLR proportional hazards pr(observe an event before  under strategy 11)
cWKM, cWLR, cWSP: sample size formulae based on weighted Kaplan–Meier estimator and weighted log rank test
with time independent weights, and sample size formula based on the weighted sample proportion estimator in Feng
and Wahed (2009), respectively;  Fj0(t),  F
j1(t): survival functions of Tj0 and T
j1, respectively; Rj: indicator for
rerandomization if assigned initial treatment j.
Table 2: Achieved powers (%) for the sample sizes based on the weighted Kaplan–
Meier estimator with time independent weights. The signiﬁcance level of the test is
5% and the desired power is 80%.
Hazard ratio nK(n) % rerandomized cWKM tWKM Lunceford 3 WT
25 88 91 85 93
1.25 2862(2995) 50 83 85 82 87
75 81 83 76 85
25 87 92 85 91
1.5 880(934) 50 82 84 76 88
75 81 82 77 83
25 87 90 78 87
2 278(307) 50 83 85 71 83
75 80 82 68 81
nK, n: sample sizes calculated from (3) and from the formula in Feng and Wahed (2009), respectively;
cWKM, tWKM: the tests based on the weighted Kaplan–Meier estimator with time independent and time
dependent weights, respectively; Lunceford 3: the test based on the third estimator in Lunceford et al.
(2002); WT: the test based on the estimator in Wahed and Tsiatis (2006).
18Table 3: Achieved powers (%) of the weighted log rank tests under sample sizes ob-
tained by cWLR. The signiﬁcance level of the test is 5% and the desired power is 80%.
25% rerandomized 50% rerandomized 75% rerandomized
Hazard ratio nL cWLR tWLR cWLR tWLR cWLR tWLR
1.25 2651 92 94 87 89 84 85
1.5 753 93 94 85 87 81 83
2 234 92 93 83 83 80 83
nL: sample size based on the weighted log rank test with time independent weights;
cWLR, tWLR: weighted log rank test with time independent weights and time dependent
weights, respectively.
19Table 4: Achieved powers (%) of tests under misspeciﬁcations of the true model. In the
true model, (T11;S1) and (T21;S2) both follow Frank copula models with association
parameters 1 and 2, respectively. The marginal distributions of T11 and T21 are Weibull
withscaleparameterandshapeparameterspeciﬁedbelow. Theﬁrstandfourthcolumns
indicate the misspeciﬁcation of the true model. All simulated powers are those of the
same tests as used to calculate the sample size. The signiﬁcance level of the tests is 5%
and the desired power is 80%.
cWKM cWLR
Speciﬁcation Speciﬁcation
of the model nK Power of the model nL Power
True model 1:
scaleT11=50, shapeT11=shapeT21=2, hazard ratio=1.25
pr(observe an event before )=0.61
no misspeciﬁcation 2862 91 no misspeciﬁcation 2651 92
scaleT11=45 2405 84 pr(event)=0.40 1726 78
scaleT11=55 3729 94 pr(event)=0.45 1953 84
shapeT11=shapeT21=1.75 3812 96 pr(event)=0.38 1658 73
shapeT11=shapeT21=2.25 2385 84 pr(event)=0.65 2825 96
exponential 2478 81 pr(event)=0.70 3045 98
True model 2:
scaleT11=50, shapeT11=shapeT12=2, hazard ratio=1.5
pr(observe an event before )=0.37
no misspeciﬁcation 880 91 no misspeciﬁcation 753 90
scaleT11=45 647 86 pr(event)=0.28 578 82
scaleT11=55 1096 94 pr(event)=0.25 510 77
shapeT11=shapeT21=1.75 978 95 pr(event)=0.36 737 71
shapeT11=shapeT21=2.25 794 83 pr(event)=0.48 973 95
exponential 601 80 pr(event)=0.50 1015 97
scaleTjk and shapeTjk: the scale and shape parameters of Tjk, respectively; pr(event):
pr(observe an event before ); exponential: the marginal distributions of T11 and T21 are
supposed to be exponential distributions with the same survival probabilities as the true
model at ; nK, nL: sample sizes calculated from (3) and (4), respectively.
20